Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Regulatory T Cell Therapy in Ulcerative Colitis
2025-520628-11-00Phase 2Authorised
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Aug 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous regulatory T cells (CD4+ CD25hi FOXP3+) in autoimmune colitis, sponsored by Universitätsklinikum Erlangen. Primary endpoint: Clinical remission at week 12 by modified Mayo score. Planned start Aug 2025; status: authorised.
02
Drugs
autologous regulatory T cells (CD4+ CD25hi FOXP3+)
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-520628-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520628-11-00.